Based on the present results, previous studies have consistently demonstrated that low ATP7A expression could result in better survival, as well as enhanced chemotherapeutic response in patients with cancer, including platinum drug resistance.[17,18] Elesclomol-induced copper chelation inhibited colorectal cancer by targeting ATP7A,[19] suggesting that ATP7A may be a potential drug treatment target. Here, ATP7A is linked to colorectal cancer.